Development of SEDDS formulation containing caffeine for dermal delivery

Objective The objective of this work was to develop a self‐emulsifying drug delivery system (SEDDS) containing caffeine for the treatment of cellulite. Methods SEDDS were prepared using the solution method. 0.5% (w/v) caffeine was added to the previously selected excipients. The system was character...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of cosmetic science 2023-04, Vol.45 (2), p.255-265
Hauptverfasser: Almeida, Igor de Andrade Assunção, Honório, Thiago da Silva, Carmo, Flavia Almada, Freitas, Zaida Maria Faria, Simon, Alice, Rangel Rodrigues, Carlos, Pereira de Sousa, Valeria, Cabral, Lucio Mendes, Abreu, Letícia Coli Louvisse
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 265
container_issue 2
container_start_page 255
container_title International journal of cosmetic science
container_volume 45
creator Almeida, Igor de Andrade Assunção
Honório, Thiago da Silva
Carmo, Flavia Almada
Freitas, Zaida Maria Faria
Simon, Alice
Rangel Rodrigues, Carlos
Pereira de Sousa, Valeria
Cabral, Lucio Mendes
Abreu, Letícia Coli Louvisse
description Objective The objective of this work was to develop a self‐emulsifying drug delivery system (SEDDS) containing caffeine for the treatment of cellulite. Methods SEDDS were prepared using the solution method. 0.5% (w/v) caffeine was added to the previously selected excipients. The system was characterized by droplet size, zeta potential, emulsification time and long‐term stability. In vitro release and skin permeation were investigated using Franz‐type diffusion cells. The cytotoxicity was evaluated on normal human keratinocytes. Results Caffeine SEDDS were thermodynamically stable, with a zeta potential less than ‐ 22 mV and droplet size around 30 nm, and were long‐term stable. The permeation study showed that the formulation promoted caffeine accumulation in the skin layers, suggesting an increase in local circulation. Cytotoxicity studies on HaCaT cells were not conclusive as the surfactant used indicated false‐positive results due to its high molar mass. Conclusion It was possible to obtain a stable SEDDS that could cause an increase in blood flow in the applied area, resulting in cellulite reduction. Abstrait Objectif L‘objectif de ce travail était de développer un système d‘administration de médicaments auto‐émulsifiants (SEDDS) contenant de la caféine pour le traitement de la cellulite. Méthodes Les SEDDS ont été préparés par la méthode en solution. 0,5 % (p/v) de caféine a été ajouté aux excipients préalablement sélectionnés. Le système a été caractérisé par la taille des gouttelettes, le potentiel zêta, le temps d‘émulsification et la stabilité à long terme. La libération in vitro et la perméation cutanée ont été étudiées dans des cellules de diffusion de type Franz. La cytotoxicité était évaluée sur des kératinocytes humains normaux. Résultats Les SEDDS de caféine étaient thermodynamiquement stables, avec un potentiel Zeta inférieur à ‐22 mV et une taille de gouttelettes d‘environ 30 nm, et stables à long terme. L‘étude de perméation a montré que les formulations favorisent l‘accumulation de caféine dans les couches de la peau, suggérant une augmentation de la circulation locale. Les études de cytotoxicité sur les cellules HaCaT n‘ont pas été concluantes car le surfactant utilisé indique des résultats faussement positifs dus à une masse molaire élevée. Conclusion Il a été possible d‘obtenir un SEDDS stable qui peut provoquer une augmentation du flux sanguin dans la zone appliquée, entraînant une réduction de la cellulite. A SEDDS formulation of caf
doi_str_mv 10.1111/ics.12841
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2774496963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2774496963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3531-808c10ee565f968aefe4302e17af8328e2ee99d8819f498f798f67191be592e03</originalsourceid><addsrcrecordid>eNp10E9LwzAYBvAgipvTg19ACl700C3_miZH2aYTBh6m55J1bySjbWayTvbtzez0IBgI7-H98fDyIHRN8JDEN7JlGBIqOTlBfcKFTClX_BT1MeE0zbhgPXQRwhpjzJVk56jHRJ5RzEQfzSawg8ptami2iTPJYjqZLBLjfN1Wemtdk5Su2Wrb2OY9KbUxYBs47JMV-FpXcVR2B35_ic6MrgJcHecAvT1OX8ezdP7y9Dx-mKclyxhJJZYlwQCZyIwSUoMBzjAFkmsjGZVAAZRaSUmUiceaPH6RE0WWkCkKmA3QXZe78e6jhbAtahtKqCrdgGtDQfOccyWUYJHe_qFr1_omXheVkhnLBSNR3Xeq9C4ED6bYeFtrvy8ILg71FrHe4rveaG-Oie2yhtWv_OkzglEHPm0F-_-Tiufxoov8Ai3cgjk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2798537631</pqid></control><display><type>article</type><title>Development of SEDDS formulation containing caffeine for dermal delivery</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Almeida, Igor de Andrade Assunção ; Honório, Thiago da Silva ; Carmo, Flavia Almada ; Freitas, Zaida Maria Faria ; Simon, Alice ; Rangel Rodrigues, Carlos ; Pereira de Sousa, Valeria ; Cabral, Lucio Mendes ; Abreu, Letícia Coli Louvisse</creator><creatorcontrib>Almeida, Igor de Andrade Assunção ; Honório, Thiago da Silva ; Carmo, Flavia Almada ; Freitas, Zaida Maria Faria ; Simon, Alice ; Rangel Rodrigues, Carlos ; Pereira de Sousa, Valeria ; Cabral, Lucio Mendes ; Abreu, Letícia Coli Louvisse</creatorcontrib><description>Objective The objective of this work was to develop a self‐emulsifying drug delivery system (SEDDS) containing caffeine for the treatment of cellulite. Methods SEDDS were prepared using the solution method. 0.5% (w/v) caffeine was added to the previously selected excipients. The system was characterized by droplet size, zeta potential, emulsification time and long‐term stability. In vitro release and skin permeation were investigated using Franz‐type diffusion cells. The cytotoxicity was evaluated on normal human keratinocytes. Results Caffeine SEDDS were thermodynamically stable, with a zeta potential less than ‐ 22 mV and droplet size around 30 nm, and were long‐term stable. The permeation study showed that the formulation promoted caffeine accumulation in the skin layers, suggesting an increase in local circulation. Cytotoxicity studies on HaCaT cells were not conclusive as the surfactant used indicated false‐positive results due to its high molar mass. Conclusion It was possible to obtain a stable SEDDS that could cause an increase in blood flow in the applied area, resulting in cellulite reduction. Abstrait Objectif L‘objectif de ce travail était de développer un système d‘administration de médicaments auto‐émulsifiants (SEDDS) contenant de la caféine pour le traitement de la cellulite. Méthodes Les SEDDS ont été préparés par la méthode en solution. 0,5 % (p/v) de caféine a été ajouté aux excipients préalablement sélectionnés. Le système a été caractérisé par la taille des gouttelettes, le potentiel zêta, le temps d‘émulsification et la stabilité à long terme. La libération in vitro et la perméation cutanée ont été étudiées dans des cellules de diffusion de type Franz. La cytotoxicité était évaluée sur des kératinocytes humains normaux. Résultats Les SEDDS de caféine étaient thermodynamiquement stables, avec un potentiel Zeta inférieur à ‐22 mV et une taille de gouttelettes d‘environ 30 nm, et stables à long terme. L‘étude de perméation a montré que les formulations favorisent l‘accumulation de caféine dans les couches de la peau, suggérant une augmentation de la circulation locale. Les études de cytotoxicité sur les cellules HaCaT n‘ont pas été concluantes car le surfactant utilisé indique des résultats faussement positifs dus à une masse molaire élevée. Conclusion Il a été possible d‘obtenir un SEDDS stable qui peut provoquer une augmentation du flux sanguin dans la zone appliquée, entraînant une réduction de la cellulite. A SEDDS formulation of caffeine was developed with a reduced droplet size and great accumulation in the dermis, favouring its action in the reduction of cellulite.</description><identifier>ISSN: 0142-5463</identifier><identifier>EISSN: 1468-2494</identifier><identifier>DOI: 10.1111/ics.12841</identifier><identifier>PMID: 36752036</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Accumulation ; administration cutané ; Blood flow ; Caffeine ; Caffeine - pharmacology ; caféine ; Cellulite ; culture cellulaire HaCat ; Cytotoxicity ; dermal delivery ; Diffusion ; Diffusion cells ; Droplets ; Drug delivery ; Drug delivery systems ; Drug Delivery Systems - methods ; Emulsification ; Emulsifying Agents ; Emulsions ; Excipients ; Formulation SEDDS ; HaCat cell culture ; Humans ; Keratinocytes ; Permeation ; SEDDS formulation ; Solubility ; Surface-Active Agents ; Surfactants ; Toxicity ; Zeta potential</subject><ispartof>International journal of cosmetic science, 2023-04, Vol.45 (2), p.255-265</ispartof><rights>2023 Society of Cosmetic Scientists and Societe Francaise de Cosmetologie.</rights><rights>Copyright © 2023 Society of Cosmetic Scientists and the Société Française de Cosmétologie</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3531-808c10ee565f968aefe4302e17af8328e2ee99d8819f498f798f67191be592e03</citedby><cites>FETCH-LOGICAL-c3531-808c10ee565f968aefe4302e17af8328e2ee99d8819f498f798f67191be592e03</cites><orcidid>0000-0002-4550-5729 ; 0000-0002-3616-3667</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fics.12841$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fics.12841$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36752036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Almeida, Igor de Andrade Assunção</creatorcontrib><creatorcontrib>Honório, Thiago da Silva</creatorcontrib><creatorcontrib>Carmo, Flavia Almada</creatorcontrib><creatorcontrib>Freitas, Zaida Maria Faria</creatorcontrib><creatorcontrib>Simon, Alice</creatorcontrib><creatorcontrib>Rangel Rodrigues, Carlos</creatorcontrib><creatorcontrib>Pereira de Sousa, Valeria</creatorcontrib><creatorcontrib>Cabral, Lucio Mendes</creatorcontrib><creatorcontrib>Abreu, Letícia Coli Louvisse</creatorcontrib><title>Development of SEDDS formulation containing caffeine for dermal delivery</title><title>International journal of cosmetic science</title><addtitle>Int J Cosmet Sci</addtitle><description>Objective The objective of this work was to develop a self‐emulsifying drug delivery system (SEDDS) containing caffeine for the treatment of cellulite. Methods SEDDS were prepared using the solution method. 0.5% (w/v) caffeine was added to the previously selected excipients. The system was characterized by droplet size, zeta potential, emulsification time and long‐term stability. In vitro release and skin permeation were investigated using Franz‐type diffusion cells. The cytotoxicity was evaluated on normal human keratinocytes. Results Caffeine SEDDS were thermodynamically stable, with a zeta potential less than ‐ 22 mV and droplet size around 30 nm, and were long‐term stable. The permeation study showed that the formulation promoted caffeine accumulation in the skin layers, suggesting an increase in local circulation. Cytotoxicity studies on HaCaT cells were not conclusive as the surfactant used indicated false‐positive results due to its high molar mass. Conclusion It was possible to obtain a stable SEDDS that could cause an increase in blood flow in the applied area, resulting in cellulite reduction. Abstrait Objectif L‘objectif de ce travail était de développer un système d‘administration de médicaments auto‐émulsifiants (SEDDS) contenant de la caféine pour le traitement de la cellulite. Méthodes Les SEDDS ont été préparés par la méthode en solution. 0,5 % (p/v) de caféine a été ajouté aux excipients préalablement sélectionnés. Le système a été caractérisé par la taille des gouttelettes, le potentiel zêta, le temps d‘émulsification et la stabilité à long terme. La libération in vitro et la perméation cutanée ont été étudiées dans des cellules de diffusion de type Franz. La cytotoxicité était évaluée sur des kératinocytes humains normaux. Résultats Les SEDDS de caféine étaient thermodynamiquement stables, avec un potentiel Zeta inférieur à ‐22 mV et une taille de gouttelettes d‘environ 30 nm, et stables à long terme. L‘étude de perméation a montré que les formulations favorisent l‘accumulation de caféine dans les couches de la peau, suggérant une augmentation de la circulation locale. Les études de cytotoxicité sur les cellules HaCaT n‘ont pas été concluantes car le surfactant utilisé indique des résultats faussement positifs dus à une masse molaire élevée. Conclusion Il a été possible d‘obtenir un SEDDS stable qui peut provoquer une augmentation du flux sanguin dans la zone appliquée, entraînant une réduction de la cellulite. A SEDDS formulation of caffeine was developed with a reduced droplet size and great accumulation in the dermis, favouring its action in the reduction of cellulite.</description><subject>Accumulation</subject><subject>administration cutané</subject><subject>Blood flow</subject><subject>Caffeine</subject><subject>Caffeine - pharmacology</subject><subject>caféine</subject><subject>Cellulite</subject><subject>culture cellulaire HaCat</subject><subject>Cytotoxicity</subject><subject>dermal delivery</subject><subject>Diffusion</subject><subject>Diffusion cells</subject><subject>Droplets</subject><subject>Drug delivery</subject><subject>Drug delivery systems</subject><subject>Drug Delivery Systems - methods</subject><subject>Emulsification</subject><subject>Emulsifying Agents</subject><subject>Emulsions</subject><subject>Excipients</subject><subject>Formulation SEDDS</subject><subject>HaCat cell culture</subject><subject>Humans</subject><subject>Keratinocytes</subject><subject>Permeation</subject><subject>SEDDS formulation</subject><subject>Solubility</subject><subject>Surface-Active Agents</subject><subject>Surfactants</subject><subject>Toxicity</subject><subject>Zeta potential</subject><issn>0142-5463</issn><issn>1468-2494</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E9LwzAYBvAgipvTg19ACl700C3_miZH2aYTBh6m55J1bySjbWayTvbtzez0IBgI7-H98fDyIHRN8JDEN7JlGBIqOTlBfcKFTClX_BT1MeE0zbhgPXQRwhpjzJVk56jHRJ5RzEQfzSawg8ptami2iTPJYjqZLBLjfN1Wemtdk5Su2Wrb2OY9KbUxYBs47JMV-FpXcVR2B35_ic6MrgJcHecAvT1OX8ezdP7y9Dx-mKclyxhJJZYlwQCZyIwSUoMBzjAFkmsjGZVAAZRaSUmUiceaPH6RE0WWkCkKmA3QXZe78e6jhbAtahtKqCrdgGtDQfOccyWUYJHe_qFr1_omXheVkhnLBSNR3Xeq9C4ED6bYeFtrvy8ILg71FrHe4rveaG-Oie2yhtWv_OkzglEHPm0F-_-Tiufxoov8Ai3cgjk</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Almeida, Igor de Andrade Assunção</creator><creator>Honório, Thiago da Silva</creator><creator>Carmo, Flavia Almada</creator><creator>Freitas, Zaida Maria Faria</creator><creator>Simon, Alice</creator><creator>Rangel Rodrigues, Carlos</creator><creator>Pereira de Sousa, Valeria</creator><creator>Cabral, Lucio Mendes</creator><creator>Abreu, Letícia Coli Louvisse</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QR</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4550-5729</orcidid><orcidid>https://orcid.org/0000-0002-3616-3667</orcidid></search><sort><creationdate>202304</creationdate><title>Development of SEDDS formulation containing caffeine for dermal delivery</title><author>Almeida, Igor de Andrade Assunção ; Honório, Thiago da Silva ; Carmo, Flavia Almada ; Freitas, Zaida Maria Faria ; Simon, Alice ; Rangel Rodrigues, Carlos ; Pereira de Sousa, Valeria ; Cabral, Lucio Mendes ; Abreu, Letícia Coli Louvisse</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3531-808c10ee565f968aefe4302e17af8328e2ee99d8819f498f798f67191be592e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Accumulation</topic><topic>administration cutané</topic><topic>Blood flow</topic><topic>Caffeine</topic><topic>Caffeine - pharmacology</topic><topic>caféine</topic><topic>Cellulite</topic><topic>culture cellulaire HaCat</topic><topic>Cytotoxicity</topic><topic>dermal delivery</topic><topic>Diffusion</topic><topic>Diffusion cells</topic><topic>Droplets</topic><topic>Drug delivery</topic><topic>Drug delivery systems</topic><topic>Drug Delivery Systems - methods</topic><topic>Emulsification</topic><topic>Emulsifying Agents</topic><topic>Emulsions</topic><topic>Excipients</topic><topic>Formulation SEDDS</topic><topic>HaCat cell culture</topic><topic>Humans</topic><topic>Keratinocytes</topic><topic>Permeation</topic><topic>SEDDS formulation</topic><topic>Solubility</topic><topic>Surface-Active Agents</topic><topic>Surfactants</topic><topic>Toxicity</topic><topic>Zeta potential</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Almeida, Igor de Andrade Assunção</creatorcontrib><creatorcontrib>Honório, Thiago da Silva</creatorcontrib><creatorcontrib>Carmo, Flavia Almada</creatorcontrib><creatorcontrib>Freitas, Zaida Maria Faria</creatorcontrib><creatorcontrib>Simon, Alice</creatorcontrib><creatorcontrib>Rangel Rodrigues, Carlos</creatorcontrib><creatorcontrib>Pereira de Sousa, Valeria</creatorcontrib><creatorcontrib>Cabral, Lucio Mendes</creatorcontrib><creatorcontrib>Abreu, Letícia Coli Louvisse</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Chemoreception Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cosmetic science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Almeida, Igor de Andrade Assunção</au><au>Honório, Thiago da Silva</au><au>Carmo, Flavia Almada</au><au>Freitas, Zaida Maria Faria</au><au>Simon, Alice</au><au>Rangel Rodrigues, Carlos</au><au>Pereira de Sousa, Valeria</au><au>Cabral, Lucio Mendes</au><au>Abreu, Letícia Coli Louvisse</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of SEDDS formulation containing caffeine for dermal delivery</atitle><jtitle>International journal of cosmetic science</jtitle><addtitle>Int J Cosmet Sci</addtitle><date>2023-04</date><risdate>2023</risdate><volume>45</volume><issue>2</issue><spage>255</spage><epage>265</epage><pages>255-265</pages><issn>0142-5463</issn><eissn>1468-2494</eissn><abstract>Objective The objective of this work was to develop a self‐emulsifying drug delivery system (SEDDS) containing caffeine for the treatment of cellulite. Methods SEDDS were prepared using the solution method. 0.5% (w/v) caffeine was added to the previously selected excipients. The system was characterized by droplet size, zeta potential, emulsification time and long‐term stability. In vitro release and skin permeation were investigated using Franz‐type diffusion cells. The cytotoxicity was evaluated on normal human keratinocytes. Results Caffeine SEDDS were thermodynamically stable, with a zeta potential less than ‐ 22 mV and droplet size around 30 nm, and were long‐term stable. The permeation study showed that the formulation promoted caffeine accumulation in the skin layers, suggesting an increase in local circulation. Cytotoxicity studies on HaCaT cells were not conclusive as the surfactant used indicated false‐positive results due to its high molar mass. Conclusion It was possible to obtain a stable SEDDS that could cause an increase in blood flow in the applied area, resulting in cellulite reduction. Abstrait Objectif L‘objectif de ce travail était de développer un système d‘administration de médicaments auto‐émulsifiants (SEDDS) contenant de la caféine pour le traitement de la cellulite. Méthodes Les SEDDS ont été préparés par la méthode en solution. 0,5 % (p/v) de caféine a été ajouté aux excipients préalablement sélectionnés. Le système a été caractérisé par la taille des gouttelettes, le potentiel zêta, le temps d‘émulsification et la stabilité à long terme. La libération in vitro et la perméation cutanée ont été étudiées dans des cellules de diffusion de type Franz. La cytotoxicité était évaluée sur des kératinocytes humains normaux. Résultats Les SEDDS de caféine étaient thermodynamiquement stables, avec un potentiel Zeta inférieur à ‐22 mV et une taille de gouttelettes d‘environ 30 nm, et stables à long terme. L‘étude de perméation a montré que les formulations favorisent l‘accumulation de caféine dans les couches de la peau, suggérant une augmentation de la circulation locale. Les études de cytotoxicité sur les cellules HaCaT n‘ont pas été concluantes car le surfactant utilisé indique des résultats faussement positifs dus à une masse molaire élevée. Conclusion Il a été possible d‘obtenir un SEDDS stable qui peut provoquer une augmentation du flux sanguin dans la zone appliquée, entraînant une réduction de la cellulite. A SEDDS formulation of caffeine was developed with a reduced droplet size and great accumulation in the dermis, favouring its action in the reduction of cellulite.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36752036</pmid><doi>10.1111/ics.12841</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-4550-5729</orcidid><orcidid>https://orcid.org/0000-0002-3616-3667</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0142-5463
ispartof International journal of cosmetic science, 2023-04, Vol.45 (2), p.255-265
issn 0142-5463
1468-2494
language eng
recordid cdi_proquest_miscellaneous_2774496963
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Accumulation
administration cutané
Blood flow
Caffeine
Caffeine - pharmacology
caféine
Cellulite
culture cellulaire HaCat
Cytotoxicity
dermal delivery
Diffusion
Diffusion cells
Droplets
Drug delivery
Drug delivery systems
Drug Delivery Systems - methods
Emulsification
Emulsifying Agents
Emulsions
Excipients
Formulation SEDDS
HaCat cell culture
Humans
Keratinocytes
Permeation
SEDDS formulation
Solubility
Surface-Active Agents
Surfactants
Toxicity
Zeta potential
title Development of SEDDS formulation containing caffeine for dermal delivery
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T12%3A42%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20SEDDS%20formulation%20containing%20caffeine%20for%20dermal%20delivery&rft.jtitle=International%20journal%20of%20cosmetic%20science&rft.au=Almeida,%20Igor%20de%20Andrade%20Assun%C3%A7%C3%A3o&rft.date=2023-04&rft.volume=45&rft.issue=2&rft.spage=255&rft.epage=265&rft.pages=255-265&rft.issn=0142-5463&rft.eissn=1468-2494&rft_id=info:doi/10.1111/ics.12841&rft_dat=%3Cproquest_cross%3E2774496963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2798537631&rft_id=info:pmid/36752036&rfr_iscdi=true